First Statistical Data from the Trials

In today’s post, we would like to update you on Optimov’s VAPA project and clinical trials. We are happy to announce our first statistical proof of the effectiveness of our platform. We are going to show you some of the data comparing the patients’ condition in the beginning of the clinical trials and after the first 3 months. At the end, we are sharing an interview with José regarding the current situation with the trials Read more…

MedTech Innovation & Crossfunctionality in University College Copenhagen

Over the past couple of months Optimov has been a learning playground for 2 groups of students, from CBS and University College Copenhagen. The innovative field (MedTech) we operate in is interesting for both healthcare students, but also business students. In the following article, we are going to share the experience of 2 students from the Nutrition and Health education from University College Copenhagen. Practical Placement in a MedTech Startup Anne and Christian had their Read more…

Optimover telerehabilitation

Same Product, Different Story – Telerehabilitation with Optimov

We are all different from each other, everyone has different needs and experiences things in a different way and we love to hear how our users experience telerehabilitation with Optimov. We believe that inspiration comes from those differences and this is why we love to share their stories – the stories of our Optimovers. We hope to inspire more people to pluck up courage to try innovative solutions, such as Optimov, to improve their life. Read more…

Successful telerehab with the optimov app

Optimover of the Month – Henry Talking about Training with the Optimov App

Having IPF and Training with the Optimov App In today’s post we are going to share an interview with the Optimover of the month – Henry, who trains with the Optimov app every day. Henry was diagnosed with IPF on the 6/6 2017 . For those not familiar, IPF (idiopathic pulmonary fibrosis) is a chronic lung disease causing a progressive and irreversible decline in lung function. The main symptom is shortness of breath and a dry Read more…

Optimov's scaling and clinical trials

The Clinical Trials – Optimov’s Scaling Until March

In today’s post, we would like to update you on Optimov’s VAPA project and its scaling, from the beginning of the clinical trials in February, until today. We are going to compare the current statistics with those from our previous scaling publication. At the end, we are sharing an interview with José regarding the status quo here in Denmark and in Finland. In our first scaling post we introduced you to the project, so we will Read more…